Harmon Cyrus's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Sep 5, 2023
- Accession no.
- 0001415889-23-012922
- Filed
- Sep 5, 2023
- Trade date
- Aug 31-Sep 5, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $256.6K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harmon CyrusCIK 0001831410 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 31, 2023 | Common Stock | SSaleDisposed | −15,000 | $9.36 | −$140,400 | 1,008,714 | Direct | |
| Sep 5, 2023 | Common Stock | SSaleDisposed | −10,000 | $11.62 | −$116,200 | 998,714 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.